AmbioPharm is a U.S.-based contract development and manufacturing organisation (CDMO) that specialises in peptide synthesis and pharmaceutical manufacturing.

Founded in 2004, AmbioPharm offers custom peptide manufacturing services, including solid-phase and liquid-phase peptide synthesis. The company operates from multiple facilities in the U.S. and China, supporting global pharmaceutical and biotechnology clients.

Key products and services:

• Custom peptide synthesis (solid-phase and liquid-phase)
• GMP peptide manufacturing
• Fragment-based peptide synthesis
• Peptide purification and isolation
• Full contract manufacturing services

AmbioPharm combines cutting-edge technology with a skilled workforce to meet the growing demand for therapeutic peptides and support the global pharmaceutical supply chain.